WILMINGTON, DE — Positive results from the Phase III Bax24 trial show that baxdrostat achieved statistically significant and clinically meaningful reductions in 24-hour systolic blood pressure (SBP) among patients with treatment-resistant hypertension (rHTN), reinforcing its potential as a next-generation therapy for hard-to-control blood pressure.
At 12 weeks, patients receiving a once-daily 2 mg dose of baxdrostat on top of standard care saw substantial decreases in ambulatory 24-hour average SBP compared with placebo. The effect was consistent throughout the day and night, including during early morning hours when cardiovascular risk is typically highest. Baxdrostat was generally well tolerated, with a safety profile consistent with previous Phase III results from the BaxHTN trial.
Dr. Bryan Williams, Chair of Medicine at University College London and primary investigator, said the findings could reshape hypertension management. “The Bax24 results show that a once-daily baxdrostat regimen can deliver highly clinically meaningful reductions in 24-hour systolic blood pressure, including in the morning when patients are at greater risk of heart attack and stroke,” he noted. “Together with the BaxHTN results, we have the potential to change our treatment approach for the many patients whose hypertension remains uncontrolled despite current therapies.”
Globally, an estimated 1.4 billion people live with hypertension, and roughly half of U.S. patients on multiple medications still fail to achieve adequate blood pressure control. Persistent 24-hour hypertension significantly elevates cardiovascular risk—studies show a 9.5 mmHg increase in average systolic pressure can raise all-cause mortality by 30%.
Sharon Barr, Executive Vice President of BioPharmaceuticals R&D, emphasized baxdrostat’s unique pharmacologic advantages. “This second Phase III trial shows substantial improvement in blood pressure, reflecting its durable half-life of up to 30 hours and highly selective inhibition of aldosterone synthase,” Barr said. “We are advancing regulatory filings and expanding clinical studies of baxdrostat as both a mono- and combination-therapy for conditions where aldosterone plays a key role, including primary aldosteronism, chronic kidney disease, and heart failure prevention.”
Baxdrostat works by selectively inhibiting aldosterone synthase, a hormone that contributes to elevated blood pressure and cardiovascular risk. Earlier studies demonstrated that the therapy reaches peak blood levels within two to four hours and maintains activity for up to 30 hours.
The Bax24 results will be presented during a late-breaking session at the American Heart Association Scientific Sessions in November 2025 and submitted to regulatory authorities worldwide. If approved, baxdrostat could become the first therapy in over a decade to deliver sustained 24-hour blood pressure control for patients with treatment-resistant hypertension.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.